This research opens up novel avenues for employing anti‐CTLA‐4 antibody therapy to circumvent the onset of colitis, which is often considered the Achilles' heel of what is arguably the most efficacious treatment for certain blood cancers and/or solid tumors. This evidence concerns the gene CTLA4 and colitis.